1. A single subcutaneous injection of clenbuterol hydrochloride (0.125 mg/kg body wt.) to female Wistar rats produced a rapid increase in muscle cyclic AMP and lactate concentrations and a decrease in muscle glycogen concentrations. These changes are characteristic of muscle /J-adrenoceptor stimulation and were abolished by intraperitoneal injection of propranolol (12.5 mg/kg) 15 min before clenbuterol administration. 2. When this dose of clenbuterol was injected twice daily, the changes in muscle metabolite concentrations which followed its acute administration persisted until day 7 of treatment, and were accompanied by increases in muscle mass, body weight and muscle protein synthesis rate (k,). When the clenbuterol injections were preceded by propanolol injections (12.5 mg/kg administered according to the protocol described above), or if animals were treated with propranolol only, the values of these variables were not significantly different from those of sham-injected controls. 3. In rats fed on a semi-synthetic diet (PW3) supplemented with 2 mg of clenbuterol/kg of diet for 7 days, the muscle mass was greater than that of rats fed on unsupplemented PW3. The increased muscle mass was accompanied by increased muscle lactate and decreased muscle glycogen concentrations. When PW3 was supplemented with 2 mg of clenbuterol/kg and 200 mg of propranolol/kg, the increase in muscle mass remained, but decreased muscle glycogen concentrations and increased muscle lactate concentrations were also observed. 4. These data are consistent with the hypothesis that clenbuterol influences muscle growth via ,-adrenoceptor stimulation.
INTRODUCTION
Numerous studies have demonstrated that administration of fl-adrenergic agonists to a variety of species causes increased muscle growth and alterations in body composition (Yang & McElligott, 1989) . Particular interest has focused on the effects of the ,82-agonist clenbuterol [4-amino-(t-butylamino)methyl-3,5-dichlorobenzyl alcohol]. In rats fed on a normal diet (Reeds et al., 1986) or one which is protein-deficient (Rothwell & Stock, 1987) , this agent causes an increase in muscle protein deposition and a decrease in the ratio of total body protein to total body fat. Clenbuterol also reverses denervation-induced muscle atrophy (Maltin et al., 1987b; Zeman et al., 1987) . A key question regarding the biochemical basis of these effects concerns whether clenbuterol and similar drugs alter body composition by fl-adrenoceptor stimulation or by another mechanism. There is evidence to support both possibilities; for example, Zeman et al. (1988) reported that chronic treatment with clenbuterol caused hypertrophy of fast-twitch muscle fibres, whereas the /?2-antagonist butoximine decreased fast-twitch fibre size, suggesting that clenbuterol influences muscle growth by ,-adrenoceptor stimulation. In contrast, Maltin et al. (1987a) found that addition of propranolol to clenbuterol-supplemented diets did not attenuate the hypertrophy of innervated (Maltin et al., 1987a) or denervated (Maltin et al., 1989) soleus muscles induced by clenbuterol. Furthermore, the dose of propranolol employed in those studies inhibited the effects of clenbuterol on energy expenditure and on fat and liver mass (Reeds et al., 1988) . These reports suggest that clenbuterol may exert a physiological response despite fl-blockade; however, no results were presented to demonstrate that, in those experiments, propranolol fully blocked the /,-adrenergic effects of clenbuterol on muscle. In this study our aim was to resolve the question of whether or not it is necessary for ,-adrenoceptor stimulation to occur for clenbuterol to exert its effects on body composition. We have therefore re-investigated the effects of treatment with clenbuterol and propranolol on muscle growth. To ensure that propranolol fully blocked the ,-adrenoceptor-stimulatory activity of clenbuterol in our experiments, we 
Metabolite determinations
Neutralized HC104 extracts of muscle and liver (Lowry & Passonneau, 1972) were prepared for determination of lactate concentrations (Gutman & Wahlefeld, 1974) . Glycogen concentrations in muscle and liver were measured by the method of Keppler & Decker (1974) . Protein was assayed by the method of Lowry et al. (1951) . Muscle and liver samples were extracted for assay of tissue cyclic AMP concentrations by the procedure described by Albano et al. (1974) . Briefly, frozen tissue was homogenized in 10 vol. of 0.5 M-HC104 containing 25% (v/v) ethanol. The homogenate was centrifuged at 1200 g for 20 min (4°C) and a sample of the neutralized supernatant was evaporated to dryness and then resuspended in the assay buffer (50 mM-Tris/4 mM-EDTA, pH 7.5). Recoveries of cyclic AMP were 95-107 0% with this procedure. The cyclic AMP assay was performed with an Amersham kit.
Determination of muscle protein synthesis rate
This was done by the method of Garlick et al. (1980) , with the modifications described by Jepson et al. (1986) . Briefly, conscious rats were injected intraperitoneally with a solution of 150 mM-[3H]pheny1alanine (35,uCi/ml) in 150 mM-NaCl (2 ml/100 g body wt.). Some 15 min later the animals were killed by a blow to the head. Both hindlimbs were then rapidly skinned and placed in a mixture of ice and water. The exact time (t) from injection of radioisotope to immersion of limbs was noted. The gastrocnemius and plantaris group of muscles was removed and placed in liquid N2 before determination of the specific radioactivity of free (SA) and protein-bound (SB) phenylalanine. Muscle k, was calculated from the equation ks (/day) 9SB x 1000% (Jepson et al. 1986 ). The muscle RNA concentration was determined by the method of Munro & Fleck (1969 12.5 mg/kg per day) and a fourth group with both propranolol and clenbuterol. Final intraperitoneal and subcutaneous injections were administered between 09:00 and 10:00 h 7 days after the treatment commenced. At 20 min after the final subcutaneous injection, the animals were anaesthetized (as described above). Then 10 min later gastrocnemius and soleus muscles (from the left hind-limb) and a sample of liver were rapidly excised and frozen in liquid N2 before metabolite analyses. The gastrocnemius and plantaris group of muscles and the soleus muscle from the contralateral limb were carefully dissected and weighed, and then frozen in liquid N2 for subsequent determination of protein content.
Expt. 3. For this, 16 female Wistar rats (123 +6 g) were divided into four groups of equal mean body weight, consisting of four animals per group. The procedure for injecting the different animal groups was identical with that in Expt. 2. At 30 min after the final subcutaneous injection on the morning of day 7 of treatment, muscle protein synthesis rates and RNA concentrations were determined.
Expt. 4. For this, 20 female Wistar rats (104-113 g) were fed on the semi-synthetic powdered diet PW3 (Pullar & Webster, 1977) ad libitum for 4 days. Each rat was then allocated to one of four groups of equal mean body weight (126 g) consisting of five rats per group. One group was maintained on PW3 diet, a second group PW3 containing 2 mg of clenbuterol/kg of diet, a third group PW3 containing 200 mg of propranolol/kg of diet, and a fourth group PW3 containing clenbuterol and propranolol at the doses stated above. After consuming the diets for 7 days, the animals were anaesthetized, and muscles and liver were removed as described in the protocol for Expt. 2.
RESULTS AND DISCUSSION Acute effects of clenbuterol and propranolol injection (Expt. 1) Within 0.5 h after a single subcutaneous injection of clenbuterol there was an increase of some 2-fold in the cyclic AMP concentration of gastrocnemius muscle, which persisted for at least 5 h (Fig. 1) . The cyclic AMP concentration of liver was unaltered by injection of clenbuterol (results not shown). Increased muscle cyclic AMP concentrations in response to ,J-adrenoceptor stimulation have previously been observed (see, e.g., Posner et al., 1965; Bowman et al., 1985) . Over the 5 h period there was also a progressive depletion of gastrocnemius and soleus muscle glycogen concentrations (Fig. 1 b) and an elevation of muscle lactate concentrations ( Fig. 1 c) , which achieved statistical significance 2 h after clenbuterol injection. The muscle and liver cyclic AMP, )* * ished by propranolol administration (Fig. 1) (Cohen, 1978) . Chronic clenbuterol treatment also resulted in an increased ks in gastrocnemius muscles (Table 3 ). The RNA concentration of gastrocnemius muscles (i.e. the 'protein synthetic capacity') from clenbuterol-treated animals was increased, as was the amount of protein synthesized per unit of RNA per day (kRNA) (Millward, 1980) . These The increased muscle RNA/protein ratio observed in the present study after clenbuterol treatment has not previously been reported in intact animals. In the previous study in which administration of clenbuterol caused increased muscle k, (Emery et al., 1984) , RNA/protein ratios were not reported. When clenbuterol was administered in such a way as to cause muscle hypertrophy but no change in muscle ks, the RNA/protein ratio was unaltered (e.g. Reeds et al., 1988) . However, the increased muscle protein content and k, of clenbuterol-treated denervated soleus muscles (Maltin et al., 1987b ) was accompanied by a transient increase in muscle RNA/ protein ratio. Thus it appears that under circumstances in which clenbuterol administration causes increased muscle ks the muscle RNA/protein ratio is also increased.
In the present study, the increased muscle protein deposition observed in animals treated with clenbuterol may have been partly the consequence of an altered rate of muscle protein degradation (kd). No method exists whereby the muscle kd may be directly determined in the rat in vivo, and our data do not provide an adequate basis from which to make an indirect estimate of the rate of this process. Indeed, to arrive at a quantitative determination of kd in muscle, it would theoretically have been necessary to measure the rate of protein synthesis at all times throughout the entire experimental period. Effects of dietary supplementation with low doses of clenbuterol and propranolol (Expt. 4) Maltin et al. (1987a Maltin et al. ( , 1989 since Herbert et al. (1985) demonstrated that gastric infusion of clenbuterol produced an effect on sheep heart rate for only 36 h, whereas the effects of the drug on nitrogen retention persisted.
The ,-adrenergic effects of clenbuterol on muscle may also be less sensitive to propranolol than the fl-adrenergic effects of the drug on other tissues. Reeds et al. (1988) reported that the dose of propranolol employed in Expt. 4 of the present study inhibited the effects of clenbuterol on cardiac, fat and liver mass and on energy expenditure, whereas the effects of clenbuterol on muscle growth remained. However, Expt. 4 of the present study has demonstrated that under these experimental conditions the effects of clenbuterol on muscle glycogen and lactate concentrations (characteristic 8-adrenergic effects) persisted despite propranolol administration. The Wistar rats used in the present study may show different sensitivities to the muscle-growth and fl-effects of clenbuterol compared with the Hooded Lister animals used by Maltin et al. (1987a Maltin et al. ( , 1989 and Reeds et al. (1988) . However, in Expt. 4 of our study, clenbuterolinduced cardiac hypertrophy was not statistically significant, whereas in the study of Reeds et al. (1988) fl-mediated (Reeds et al., 1988) 
